545 related articles for article (PubMed ID: 33196851)
21. CRISPR/Cas9 in epigenetics studies of health and disease.
Sar P; Dalai S
Prog Mol Biol Transl Sci; 2021; 181():309-343. PubMed ID: 34127198
[TBL] [Abstract][Full Text] [Related]
22. Regulation of Gene Expression Using dCas9-SunTag Platforms.
Morita S; Horii T; Hatada I
Methods Mol Biol; 2023; 2577():189-195. PubMed ID: 36173574
[TBL] [Abstract][Full Text] [Related]
23. Refining CRISPR-based genome and epigenome editing off-targets.
Luo Y
Cell Biol Toxicol; 2019 Aug; 35(4):281-283. PubMed ID: 31227932
[No Abstract] [Full Text] [Related]
24. CRISPR Tools for Physiology and Cell State Changes: Potential of Transcriptional Engineering and Epigenome Editing.
Breunig CT; Köferle A; Neuner AM; Wiesbeck MF; Baumann V; Stricker SH
Physiol Rev; 2021 Jan; 101(1):177-211. PubMed ID: 32525760
[TBL] [Abstract][Full Text] [Related]
25. In vivo epigenome editing and transcriptional modulation using CRISPR technology.
Lau CH; Suh Y
Transgenic Res; 2018 Dec; 27(6):489-509. PubMed ID: 30284145
[TBL] [Abstract][Full Text] [Related]
26. A modular dCas9-SunTag DNMT3A epigenome editing system overcomes pervasive off-target activity of direct fusion dCas9-DNMT3A constructs.
Pflueger C; Tan D; Swain T; Nguyen T; Pflueger J; Nefzger C; Polo JM; Ford E; Lister R
Genome Res; 2018 Aug; 28(8):1193-1206. PubMed ID: 29907613
[TBL] [Abstract][Full Text] [Related]
27. Designing Epigenome Editors: Considerations of Biochemical and Locus Specificities.
Sen D; Keung AJ
Methods Mol Biol; 2018; 1767():65-87. PubMed ID: 29524129
[TBL] [Abstract][Full Text] [Related]
28. Technologies for targeting DNA methylation modifications: Basic mechanism and potential application in cancer.
Wang J; Yang J; Li D; Li J
Biochim Biophys Acta Rev Cancer; 2021 Jan; 1875(1):188454. PubMed ID: 33075468
[TBL] [Abstract][Full Text] [Related]
29. Chromatin Manipulation and Editing: Challenges, New Technologies and Their Use in Plants.
Fal K; Tomkova D; Vachon G; Chabouté ME; Berr A; Carles CC
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33419220
[TBL] [Abstract][Full Text] [Related]
30. A Review on CRISPR-mediated Epigenome Editing: A Future Directive for Therapeutic Management of Cancer.
Chakravarti R; Lenka SK; Gautam A; Singh R; Ravichandiran V; Roy S; Ghosh D
Curr Drug Targets; 2022; 23(8):836-853. PubMed ID: 35078394
[TBL] [Abstract][Full Text] [Related]
31. Development of Toolboxes for Precision Genome/Epigenome Editing and Imaging of Epigenetics.
Nomura W
Chem Rec; 2018 Dec; 18(12):1717-1726. PubMed ID: 30066981
[TBL] [Abstract][Full Text] [Related]
32. Toward the Development of Epigenome Editing-Based Therapeutics: Potentials and Challenges.
Ueda J; Yamazaki T; Funakoshi H
Int J Mol Sci; 2023 Mar; 24(5):. PubMed ID: 36902207
[TBL] [Abstract][Full Text] [Related]
33. A versatile reporter system for multiplexed screening of effective epigenome editors.
Roman Azcona MS; Fang Y; Carusillo A; Cathomen T; Mussolino C
Nat Protoc; 2020 Oct; 15(10):3410-3440. PubMed ID: 32887975
[TBL] [Abstract][Full Text] [Related]
34. Genome-wide programmable transcriptional memory by CRISPR-based epigenome editing.
Nuñez JK; Chen J; Pommier GC; Cogan JZ; Replogle JM; Adriaens C; Ramadoss GN; Shi Q; Hung KL; Samelson AJ; Pogson AN; Kim JYS; Chung A; Leonetti MD; Chang HY; Kampmann M; Bernstein BE; Hovestadt V; Gilbert LA; Weissman JS
Cell; 2021 Apr; 184(9):2503-2519.e17. PubMed ID: 33838111
[TBL] [Abstract][Full Text] [Related]
35. Editing the Epigenome to Tackle Brain Disorders.
Liu XS; Jaenisch R
Trends Neurosci; 2019 Dec; 42(12):861-870. PubMed ID: 31706628
[TBL] [Abstract][Full Text] [Related]
36. Target Discovery for Precision Medicine Using High-Throughput Genome Engineering.
Guo X; Chitale P; Sanjana NE
Adv Exp Med Biol; 2017; 1016():123-145. PubMed ID: 29130157
[TBL] [Abstract][Full Text] [Related]
37. Chemical and Light Inducible Epigenome Editing.
Zhao W; Wang Y; Liang FS
Int J Mol Sci; 2020 Feb; 21(3):. PubMed ID: 32028669
[TBL] [Abstract][Full Text] [Related]
38. Waking up dormant tumor suppressor genes with zinc fingers, TALEs and the CRISPR/dCas9 system.
Garcia-Bloj B; Moses C; Sgro A; Plani-Lam J; Arooj M; Duffy C; Thiruvengadam S; Sorolla A; Rashwan R; Mancera RL; Leisewitz A; Swift-Scanlan T; Corvalan AH; Blancafort P
Oncotarget; 2016 Sep; 7(37):60535-60554. PubMed ID: 27528034
[TBL] [Abstract][Full Text] [Related]
39. Epigenome editing in cancer: Advances and challenges for potential therapeutic options.
Lee SW; Frankston CM; Kim J
Int Rev Cell Mol Biol; 2024; 383():191-230. PubMed ID: 38359969
[TBL] [Abstract][Full Text] [Related]
40. Development of super-specific epigenome editing by targeted allele-specific DNA methylation.
Rajaram N; Kouroukli AG; Bens S; Bashtrykov P; Jeltsch A
Epigenetics Chromatin; 2023 Oct; 16(1):41. PubMed ID: 37864244
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
